122 related articles for article (PubMed ID: 23295643)
21. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
DeJesus E; Rockstroh JK; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Yale K; Szwarcberg J; White K; Cheng AK; Kearney BP;
Lancet; 2012 Jun; 379(9835):2429-2438. PubMed ID: 22748590
[TBL] [Abstract][Full Text] [Related]
22. Boosting HIV treatment options: good news, new challenges.
Cahn P; Sued O
J Infect Dis; 2013 Jul; 208(1):4-6. PubMed ID: 23532095
[No Abstract] [Full Text] [Related]
23. FDA treads carefully with PrEP.
Holmes D
Lancet Infect Dis; 2012 Jul; 12(7):515-6. PubMed ID: 22930826
[No Abstract] [Full Text] [Related]
24. Cobicistat + elvitegravir + emtricitabine + tenofovir. Two new drugs, but no progress.
Prescrire Int; 2013 Oct; 22(142):233-5. PubMed ID: 24298581
[TBL] [Abstract][Full Text] [Related]
25. Novel HIV-1 treatment Stribild™ gains regulatory approval.
Breeze S
Expert Rev Clin Pharmacol; 2012 Nov; 5(6):613. PubMed ID: 23234321
[No Abstract] [Full Text] [Related]
26. Sustained virological response after taking crushed elvitegravir-cobicistat-emtricitabine-tenofovir tablets.
Fulco PP; Ayala-Sims VA
Am J Health Syst Pharm; 2014 May; 71(10):784, 786. PubMed ID: 24780482
[No Abstract] [Full Text] [Related]
27. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
Gallant JE; Koenig E; Andrade-Villanueva J; Chetchotisakd P; DeJesus E; Antunes F; Arastéh K; Moyle G; Rizzardini G; Fehr J; Liu Y; Zhong L; Callebaut C; Szwarcberg J; Rhee MS; Cheng AK
J Infect Dis; 2013 Jul; 208(1):32-9. PubMed ID: 23532097
[TBL] [Abstract][Full Text] [Related]
28. Drug updates and approvals: 2018 in review.
Mospan C; Mospan G; Byland E; Whitaker WB; Xiong L; Dunlap J; Canupp K
Nurse Pract; 2018 Dec; 43(12):23-32. PubMed ID: 30379711
[TBL] [Abstract][Full Text] [Related]
29. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
Gaur AH; Kizito H; Prasitsueubsai W; Rakhmanina N; Rassool M; Chakraborty R; Batra J; Kosalaraksa P; Luesomboon W; Porter D; Shao Y; Myers M; Ting L; SenGupta D; Quirk E; Rhee MS
Lancet HIV; 2016 Dec; 3(12):e561-e568. PubMed ID: 27765666
[TBL] [Abstract][Full Text] [Related]
30. Single-tablet regimens in HIV: does it really make a difference?
Aldir I; Horta A; Serrado M
Curr Med Res Opin; 2014 Jan; 30(1):89-97. PubMed ID: 24040862
[TBL] [Abstract][Full Text] [Related]
31. Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results.
Gallant JE; Koenig E; Andrade-Villanueva JF; Chetchotisakd P; DeJesus E; Antunes F; Arastéh K; Rizzardini G; Fehr J; Liu HC; Abram ME; Cao H; Szwarcberg J
J Acquir Immune Defic Syndr; 2015 Jul; 69(3):338-40. PubMed ID: 26181707
[TBL] [Abstract][Full Text] [Related]
32. Emtricitabine/tenofovir disoproxil fumarate.
Drugs R D; 2004; 5(3):160-1. PubMed ID: 15139777
[TBL] [Abstract][Full Text] [Related]
33. [ First integrase inhibitor based single tablet regimen].
MMW Fortschr Med; 2013 Jun; 155 Suppl 1():20-1. PubMed ID: 23961647
[No Abstract] [Full Text] [Related]
34. Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial.
Maggiolo F; Rizzardini G; Raffi F; Pulido F; Mateo-Garcia MG; Molina JM; Ong E; Shao Y; Piontkowsky D; Das M; McNicholl I; Haubrich R
Lancet HIV; 2019 Oct; 6(10):e655-e666. PubMed ID: 31578954
[TBL] [Abstract][Full Text] [Related]
35. Recent FDA approvals and changes.
AIDS Patient Care STDS; 2010 Feb; 24(2):133-4. PubMed ID: 20156092
[No Abstract] [Full Text] [Related]
36. Comment on: Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection.
Ambrosioni J; Mosquera MM; Miró JM
J Antimicrob Chemother; 2017 May; 72(5):1548-1549. PubMed ID: 28160503
[No Abstract] [Full Text] [Related]
37. Drug updates and approvals: 2015 in review.
Klibanov OM; Phan D; Ferguson K
Nurse Pract; 2015 Dec; 40(12):34-43; quiz 43-4. PubMed ID: 26545091
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' response.
Nozza S; Poli A; Ripa M; Galli L; Chiappetta S; Spagnuolo V; Rovelli C; Lazzarin A; Castagna A; Tambussi G
J Antimicrob Chemother; 2017 May; 72(5):1549-1550. PubMed ID: 28333303
[No Abstract] [Full Text] [Related]
39. Improved adherence expected with new HIV combo treatment.
Morrow T
Manag Care; 2012 Nov; 21(11):53-4. PubMed ID: 23236718
[No Abstract] [Full Text] [Related]
40. Stribild: a review of component characteristics and combination drug efficacy.
Murrell DE; Moorman JP; Harirforoosh S
Eur Rev Med Pharmacol Sci; 2015; 19(5):904-14. PubMed ID: 25807445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
